BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLAND

被引：1
|
作者：
Hollmann, S. [1 ]
Painter, C. [2 ]
Hogan, A. [1 ]
Wickstead, R. M. [2 ]
Goyert, N. [1 ]
Patel, S. [3 ]
Slowley, A. [3 ]
Jousseaume, E. [4 ]
El Ouagari, K. [5 ]
Zhang, J. [6 ]
Jewitt, K. [3 ]
Ma, Q. [6 ]
机构：
[1] Cornerstone Res Grp Inc, Burlington, ON, Canada
[2] Costello Med, London, England
[3] Novartis Pharmaceut UK Ltd, Camberley, Surrey, England
[4] Novartis Pharma AG, Basel, Switzerland
[5] Novartis Pharmaceut Canada Ltd, Dorval, PQ, Canada
[6] Novartis Pharmaceut, E Hanover, NJ USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.150
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN68
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND
    Hollmann, S.
    Painter, C.
    Hogan, A.
    Morten, P.
    Goyert, N.
    Vieira, J.
    Slowley, A.
    Jousseaume, E.
    El Ouagari, K.
    Zhang, J.
    Jewitt, K.
    Ma, Q.
    VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [2] Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
    Santasusana, Josep Maria Ribera
    de Andres Saldana, Alejandra
    Garcia-Munoz, Nuria
    Gostkorzewicz, Joana
    Martinez Llinas, Diana
    Diaz de Heredia, Cristina
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 253 - 264
  • [3] Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia
    Si Lim, Stephanie J.
    Grupp, Stephen A.
    DiNofia, Amanda M.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (09)
  • [4] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
    Wakase, Shiho
    Teshima, Takanori
    Zhang, Jie
    Ma, Qiufei
    Watanabe, Yoko
    Yang, Hongbo
    Qi, Cynthia Z.
    Chai, Xinglei
    Xie, Yanwen
    Wu, Eric Q.
    Igarashi, Ataru
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 241.e1 - 241.e11
  • [5] Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
    Wang, Xiao Jun
    Wang, Yi-Ho
    Ong, Matthew Jian Chun
    Gkitzia, Christina
    Soh, Shui Yen
    Hwang, William Ying Khee
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 333 - 355
  • [6] Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
    Hidefumi Hiramatsu
    Souichi Adachi
    Katsutsugu Umeda
    Itaru Kato
    Lamis Eldjerou
    Andrea Chassot Agostinho
    Kazuto Natsume
    Kota Tokushige
    Yoko Watanabe
    Stephan A. Grupp
    International Journal of Hematology, 2020, 111 : 303 - 310
  • [7] Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
    Hiramatsu, Hidefumi
    Adachi, Souichi
    Umeda, Katsutsugu
    Kato, Itaru
    Eldjerou, Lamis
    Agostinho, Andrea Chassot
    Natsume, Kazuto
    Tokushige, Kota
    Watanabe, Yoko
    Grupp, Stephan A.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (02) : 303 - 310
  • [8] FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
    O'Leary, Maura C.
    Lu, Xiaobin
    Huang, Ying
    Lin, Xue
    Mahmood, Iftekhar
    Przepiorka, Donna
    Gavin, Denise
    Lee, Shiowjen
    Liu, Ke
    George, Bindu
    Bryan, Wilson
    Theoret, Marc R.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1142 - 1146
  • [9] COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PAEDIATRIC AND YOUNG ADULT RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBASTIC LEUKAEMIA, FROM A GREEK SOCIAL SECURITY SYSTEM PERSPECTIVE
    Kattamis, A.
    Avgitidou, A.
    Chatzopoulos, S.
    Markouri, A.
    Florini, S.
    Stafylas, P.
    VALUE IN HEALTH, 2019, 22 : S452 - S452
  • [10] COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CANADIAN SOCIETAL PERSPECTIVE
    Yang, H.
    Zhang, J.
    Hampe, M.
    VALUE IN HEALTH, 2018, 21 : S43 - S43
12345